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Background: Visceral leishmaniasis (VL) is one of the most neglected parasitic 
diseases causing large scale mortality and morbidity among the poorest of the 
poor in the Indian subcontinent and Africa. Objective: This review aims to 
describe the potential and the (lack of) current impact of newly developed 
treatments on the control of VL. It describes how the problem of an empty 
research pipeline is addressed, and discusses the emerging threat of incurable 
HIV/VL coinfection. Methods: The literature was searched for drugs used in VL. 
Conclusion: Research and development of VL drugs has received a financial 
boost but no new drugs are expected in the next 5 years. Only three new and 
highly effective treatments have been licensed in the past 10 years. These 
remain, however, largely inaccessible as VL control programs in the developing 
world are lacking. This is deserving of immediate and urgent attention, 
especially in the context of the rapidly expanding HIV/VL coinfection.
Keywords: AmBisome, amphotericin B, antimonials, kala-azar, miltefosine, paromomycin,  
pentamidine, sodium stibogluconate, visceral leishmaniasis
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1.	 Background
Visceral leishmaniasis (VL, also called kala-azar) is a lethal vector-borne protozoal 
infection caused by different species of the Leishmania parasite, and characterized 
by fever, weight loss, hepatosplenomegaly, anemia and a depression of the immune 
system. Death is caused by the consequences of pancytopenia and opportunistic 
infections leading to pneumonia and diarrhea. In 95% of cases, death can be avoided 
by timely treatment, even in basic field circumstances [1]. After subclinical or cured 
clinical infection, long-lasting immunity prevents recurrence of VL in most patients. 
Post-kala-azar dermal leishmaniasis is a cutaneous and sometimes mucosal mani-
festation that occurs after clinical cure in 55% of Sudanese patients [2], and until 
recently in 5 – 15% of Indian patients [3]. Post-kala-azar dermal leishmaniasis can 
occur long after cure and often goes undetected, especially in the Indian subconti-
nent, and because the skin lesions are infectious to sandflies, it may be a significant 
contributor to the spread of the infection [4].
Infection is transmitted by the bite of the phlebotomine sandfly, which has fed either 
on infected humans – the anthroponotic form of VL caused by Leishmania donovani 
and found in the Indian subcontinent and eastern Africa – or has fed on infected 
dogs, the zoonotic form of VL caused by Leishmania infantum/Leishmania chagasi in 
the Mediterranean basin, the Middle East, Central Asia and South America [5].
The second largest parasitic cause of death (after malaria), VL is prevalent in 
47 countries, with ∼ 200 million at risk [6], and an annual estimated incidence 
of ∼ 500,000 cases and > ∼ 50,000 deaths [7]. Overall, 90% of cases occur in India, 
Bangladesh,  Nepal,  Sudan  and  Brazil  [6],  and  60%  in  the  Indian  subcontinent 
alone  [8]. Eastern Africa (Sudan, Ethiopia, Kenya, Uganda and Somalia) has the 
second largest number of cases (Figure 1)  [9]. The real burden of VL may be far 
higher than the number of reported cases  [7]. In Bihar, India, only one in eight 
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cases is reported through official channels [10] and ∼ 20% of 
cases end in death undiagnosed [11]. Retrospective mortality 
surveys in southern Sudan estimated that in an epidemic 
in Western  Upper  Nile  province  in  the  1980s  and  1990s, 
VL caused > 100,000 deaths in a population of 280,000 [12]. 
A  later  study  estimated  that  only  50%  of  cases  in  Sudan 
can  access  treatment,  resulting  in  ∼  90%  of  VL  deaths 
going unreported [13].
Although  also  present  in  suburban  settings,  VL  mostly 
affects the poorest of the poor, mainly in very remote rural 
regions, with malfunctioning or absent health systems  [14]. 
In East Africa and particularly in Sudan, epidemics with a 
high mortality are frequent, especially where there is a lack of 
access  to  healthcare  and  widespread  malnutrition  [1,12,15,16]. 
In India, Nepal and Bangladesh, where the incidence is steadily 
rising,  the  disease  is  associated  with  extreme  poverty  and 
overcrowding in agricultural villages [9].
The HIV pandemic in South America, Asia and Africa is 
expanding  into  rural  and  remote  VL  endemic  areas  [17]. 
HIV/VL  coinfection  is  a  rapidly  expanding  problem,  and 
makes a comprehensive approach for control of VL urgent 
and  important.  Leishmania/HIV  coinfection  is  reported  in 
35 endemic countries [17]. According to a WHO coordinated 
monitoring system including 28 institutions worldwide, the 
number of new cases has declined in Europe since the end of 
the 1990s, mainly due to access to highly active antiretroviral 
therapy (HAART) [17]. In other parts of the world, however, 
where there is little access to HAART, the prevalence is steadily 
rising, especially in northern Ethiopia, where HIV infection 
increased from 19% in 1998/99 to 34% of those affected with 
VL in 2006/07 [17-19]. In Brazil, Sudan, India and Nepal, the 
estimated prevalence has so far remained below 10% [17] but 
is expected to dramatically rise, as long as there continues to 
be little access to HAART.
HIV and VL reinforce each other in a detrimental manner. 
HIV patients are much more likely to develop VL, whereas 
VL will negatively impact the response to HAART [17]. VL 
in coinfected patients cannot be cured, and those with CD4+ 
counts < 200 cells/μl typically relapse more and more fre-
quently until they become unresponsive to all drugs used [17,20]. 
They characteristically have very high parasite loads and thus 
contribute to an increased spread of the infection [21], which 
may include the spread of drug-resistant strains. In addition, 
these  patients  have  been  proven  to  be  highly  infective  to 
sandflies [22]. In Africa, HAART is only partially effective in 
preventing VL relapse [23]. HIV/VL coinfection thus creates a 
significant threat to potentially large numbers of people and 
will form a considerable extra burden to healthcare systems, 
as management of these patients is difficult and expensive.
In terms of a lack of research and development (R&D) [24], 
a strong association with poverty, poor access to treatment, 
negligible funding for treatment and control programs, low 
Figure	1.	Distribution	of	visceral	leishmaniasis.
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media coverage [25] and significant under-reporting [9], VL is 
undoubtedly  one  of  the  most  neglected  diseases.  Recent 
developments  indicate  that  this  situation  may  improve  in 
the near future. In May 2007, the WHO hosted the First 
Global  Partners’  Meeting  on  Neglected  Tropical  Diseases, 
leading to the establishment of the Neglected Tropical Dis-
eases  Scientific  and  Technical  Advisory  Group.  Neglected 
diseases are increasingly linked to a human rights approach, 
including the right to health, education and housing, and WHO 
has published a comprehensive report on this topic [26]. Also 
in 2007, at the 60th World Health Assembly, a resolution on 
the control of leishmaniasis was accepted. As a consequence, a 
new WHO Technical Report on the Control of Leishmaniasis 
is in preparation. Meta-analyses on different aspects of the 
disease and country profiles are being developed to serve as 
background  information  for  this  report.  WHO  plans  the 
establishment of a global program in 2010 [27].
These plans are very promising. However, any large scale 
implementation of VL diagnosis and treatment programs is 
now lacking, and an immediate solution for the many patients 
that do not receive treatment today is not apparent. Treatment 
is often unavailable or unaffordable. In India, most patients 
rely on partial and substandard treatment provided by the 
private market [28], which has led to the emergence of drug 
resistance. Many poor patients are fully dependent on non-
governmental treatment programs, which only the interna-
tional medical humanitarian non-governmental organization 
Médecins Sans Frontières (MSF) provides on a relatively large 
scale in Africa and India (Bihar).
Tropical  disease  experts  are  urging  the  Global  Fund  to 
Fight AIDS, Malaria and TB to include neglected diseases in 
its funding programs  [29]. This would significantly increase 
access to treatment for VL and should be much encouraged. 
Treatment for VL as an opportunistic infection for HIV/AIDS 
can already be included in Global Fund programs, and this 
avenue for funding should be actively encouraged.
2.	 Medical	need
Research and development in the field of VL is largely focused 
on  the  basic  biological  and  immunological  aspects  of  the 
Leishmania parasite. This has led to an abundance of publi-
cations and a thorough base of knowledge that includes signifi-
cant progress in the cracking of their genetic code [27]. However, 
although these research efforts may lead to important public 
health benefits, such as the identification of new drug discovery 
targets, they are not directly linked to public health needs, and 
do not provide immediate benefits to the many patients in 
developing countries.
Research into much needed new drugs and their implemen-
tation has been stalled for many years, largely due to a lack 
of  commercial  interest  and  the  absence  of  a  public  health 
oriented R&D agenda for neglected diseases. Between 1975 
and  2004,  only  two  of  1556  novel  drug  compounds 
were  intended  for  VL  [30],  and  both  were  not  originally 
developed  for  this  indication.  Of  these,  liposomal 
amphotericin  B  (AmBisome®,  Gilead,  USA)  was  already  in 
use for fungal infections before its high therapeutic index for 
VL was discovered [31]. Miltefosine (MF), an oral treatment, 
was  originally  marketed  as  an  antineoplastic and only later 
developed  for  VL  in  cooperation  with  WHO’s  Special   
Programme  for  Research  and  Training  in  Tropical  Diseases 
(TDR) [30,32].
Prospects for drug development have improved since the 
foundation of the Institute for One World Health (iOWH) in 
2000 and the Drugs for Neglected Diseases initiative (DNDi) 
3 years later. Both non-profit institutions focus on drug develop-
ment for neglected diseases. For VL, this has so far resulted in 
the registration in India in 2006 of the low cost injectable 
drug paromomycin (PM), by iOWH  [33,34]. However, both 
these organizations are mainly dependent on philanthropic 
funding. A sustainable and structural solution for R&D in VL 
and other neglected diseases still needs to be found. Govern-
ments of the developed world should take responsibility for 
creating and funding a R&D agenda focused on meeting global 
public health needs, including diseases so far neglected by 
industry and public research institutions [24,35].
None of the recently developed treatment options for VL 
(MF, AmBisome and PM) are freely accessible for patients in 
developing countries, although they present great advantages 
over the older treatments. Research was focused only on the 
clinical development phase, but not on ensuring that the drugs 
would reach the patients that need them after clinical develop-
ment is finished. Now research is needed into the design of 
cost-effective intervention strategies in order to deliver inno-
vation to patients, taking into account their day to day reality, 
and their poor access to diagnosis and treatment.
The ideal VL treatment should be feasible in the circum-
stances in which most VL patients live: in no proximity to 
hospitals, and in such poverty that travelling costs and pro-
longed  absence  from  work  are  typically  insurmountable 
obstacles to seeking treatment [13,36]. Such a setting also makes 
the follow-up of those that eventually reach the hospital very 
difficult. Any VL treatment should, therefore, preferably be a 
short  course,  easily  administered  in  an  out-patient  setting, 
highly effective, with no known resistant strains, affordable 
and safe. None of the currently existing VL treatment options 
meet  these  criteria,  and  additionally  their  costs  form  a 
barrier (Tables 1 and 2). Treatment with pentavalent antimo-
nials (SbV) is prolonged, potentially toxic, very painful and 
ineffective in parts of India due to resistant L. donovani. Yet, 
SbV  has  remained  the  mainstay  of  treatment  in  developing 
countries  since  the  1940s.  AmBisome  and  MF  are  only 
affordable for VL patients in the developed world, while PM 
is not yet used outside Phase IV drug trials, except by MSF in 
South Sudan. Additionally, PM, MF and AmBisome are not 
yet registered by their respective manufacturers in all poor 
endemic countries (Table 2b). The efficacy and dose of VL 
drugs, except for SbV, have not been determined in Africa, 
where drug susceptibility of L. donovani may be different 
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to  L.  donovani  in  India  and  to  L.  infantum/L.  chagasi  in 
South America.
All drugs currently used for VL, except amphotericin B, 
are prone to the development of resistance, and Leishmania has 
already  developed  resistance  to  both  SbV  and  pentamidine 
in India. Because of the paucity of agents, it is important to 
prevent the emergence of further resistant strains. A consensus 
has emerged that drugs in use for humans should not be used 
in canine leishmaniasis [37] and that anthroponotic VL (with 
its potential for developing drug resistance) should be treated 
with combination regimen of drugs, rather than with mono-
therapy. Combination therapy is expected to prevent the devel-
opment  of  resistant  strains,  and  shortens  the  duration  of 
treatment, which will have a positive impact on compliance. 
As SbV resistance only developed after the drug was widely 
misused in incomplete treatment regimen, this will further 
reduce the risk of resistance.
Combination therapy will also increase efficacy, improve 
compliance, reduce side effects, be cheaper, and, therefore, 
allow for more cost-effective treatment programs. Preliminary 
results of an continuing cost-effectiveness analysis showed that 
of three possible combination regimen, AmBisome + PM is 
the most-cost effective combination ($133/death averted) [38]. 
No combinations have yet been used in treatment programs, 
except PM/sodium stibogluconate (SSG) [39,40].
There  are  only  few  clinical  studies  on  the  efficacy  of 
treatments  for  HIV/VL  coinfection,  and  most  have  been 
performed in Europe (L. infantum infections). None of the 
currently used drugs have proven effective in HIV/VL. Patients 
experience  multiple  relapses  and  become  eventually  unre-
sponsive to all drugs used  [17]. Enhanced toxicity of treat-
ments  is  frequently  experienced,  and  reduces  treatment 
options further  [17]. Possible overlapping toxicity, especially 
renal toxicity, of antiretroviral and antileishmanial treatments 
may  cause  further  problems.  Combination  regimen  should 
also be tested in coinfected patients, as they may improve 
treatment efficacy.
3.	 Existing	treatments
3.1	 Pentavalent	antimonials
Pentavalent antimonials (SbV, SSG and meglumine antimo-
niate) are derivatives of stibonic acid in which antimony is 
joined to the carbon chains of glucose. SbV has been in use for 
all forms of leishmaniasis for over 70 years and are currently 
still the mainstream treatment for VL. Throughout Sudan, cure 
rates of 95% or higher have been consistently obtained with 
a standard 30 days regimen of SbV  [1], but resistant strains 
have rendered SbV ineffective in > 60% of Indian patients in 
Bihar [41]. Despite this, SbV is still in use in India except when 
treatment is not constrained by cost or in pilot programs in 
which other drugs are in use.
SSG  was  originally  developed  in  the  1940s  for  VL  by 
Wellcome  (now  GlaxoSmithKline  (GSK))  under  the  trade 
name Pentostam®  [42]. A few years later, meglumine anti-
moniate  (Glucantime®)  was  marketed  and  is  currently 
produced  by  sanofi-aventis.  Both  were,  however,  priced 
beyond the reach of most patients in developing countries. 
In the 1990s, a cheaper generic form of SSG, produced by 
Albert  David,  India,  was  shown  to  be  equally  safe  and 
effective [19,43,44]. This generic was then introduced in Africa 
by MSF and is now used in African VL treatment programs. 
sanofi-aventis  has  now  reduced  the  price  of  Glucantime   
for  developing  countries,  similar  to  the  price  of  generic 
SSG (Table 1).
The recommended dose of SbV  is  20  mg/kg/day,  for 
28  –  30  days,  which  is  close  to  the  maximally  tolerated 
dose  [45].  SbV  is  given  either  by  intramuscular  or  by  slow 
Table	2b.	Registration	of	VL	drugs	in	VL	endemic	countries.
Pentavalent	
antimonials
Amphotericin	B AmBisome Miltefosine Paromomycin
Bangladesh Yes No No No No
Brazil Yes Yes Yes No No
Ethiopia Yes Yes No, but allowed for use on 
compassionate base
No No
Kenya Yes Yes No, but allowed for use on 
compassionate base
No No
India Yes Yes No, but MSF has permission for  
use as first-line treatment
Yes Yes
Nepal Yes Yes No No No
Sudan* Yes Yes No, but allowed for use on 
compassionate base
No No
Uganda Yes Yes No No No
*South Sudan has no drug registration authority; MSF has obtained permission to use all available VL drugs on compassionate base.
MSF: Médecins Sans Frontières; VL: Visceral leishmaniasis.
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intravenous administration. Intramuscular administration is 
painful, because it is an irritant and large volumes have to 
be given. The intravenous route is less painful but impracti-
cal when treating large numbers of patients in the field. SbV 
has a high incidence of side effects. Toxicity includes eleva-
tion  of  serum  amylase  and  liver  enzymes;  arthralgia  and 
myalgia;  thrombocytopenia; leukopenia; anorexia and throm-
bophlebitis. Electrocardiograph changes are not uncommon; 
these develop gradually and are dose-dependent and revers-
ible.  Serious  adverse  events  are  rare,  but  in  HIV  positive 
patients SbV has an unacceptable toxicity and mortality [18].
3.2	 PM
PM or aminosidine is an aminoglycoside that was originally 
licensed  by  Farmitalia  Carlo  Erba  as  a  broad  spectrum 
parenteral antibiotic against bacteria and by Parke-Davis as 
an  oral  agent  against  intestinal  protozoa.  It  was  first  used 
successfully in human VL in Kenya in the 1980s [46]. WHO 
sponsored its development in India [47] but later ran out of 
funding  [33]. After the International Dispensary Association 
(The Netherlands) brought it back into production, it was 
adopted by iOWH and a large Phase III trial showed that 
a regimen of 21 days of 15 mg/kg given as  daily  intra-
muscular  injections  was  highly  effective  with  an  excellent 
safety profile in India [34]. No nephrotoxicity, < 1% reversible 
ototoxicity  and  <  5%  minor  hepatotoxicity  were  reported. 
PM was licensed for VL in India in 2006, with registration in 
other VL endemic Asian and African countries planned. A 
Phase IV study in India is currently undertaken by iOWH, 
and  PM  is  being  evaluated  in  mono-and  combination 
therapy in East Africa by DNDi. Preliminary results indicate 
that  monotherapy  in  Sudanese  VL  has  unacceptably  low 
efficacy,  whereas  in  Ethiopian VL,  results  were  much  better. 
PM should, therefore, only be used in combination with 
other  drugs  in  Sudanese  VL.  PM  resistance  is  readily 
induced  in  vitro  [48-50].  Secondary  resistance  has  also 
been  observed  after  60  days  of  PM  injections  in  cutaneous 
leishmaniasis  [51].  PM’s  efficacy  and  safety  in  coinfected 
patients are still unknown.
3.3	 Amphotericin	B
Conventional amphotericin B, or amphotericin B deoxycholate, 
is a highly effective and relatively affordable treatment option 
for VL in all endemic regions. However, in-patient care in a 
relatively well-equipped hospital for 30 days is required because 
of the risk of potentially serious side effects (especially renal 
toxicity). This makes it unfeasible for the treatment of most 
patients. Lipid formulations of amphotericin B are much better 
tolerated and  thus  preferable  to  conventional  amphotericin 
B. Of all lipid forms, AmBisome® (Gilead, Foster City, CA, 
USA), a liposomal formulation of amphotericin B, has been 
most extensively used and tested for VL. A very high therapeutic 
index, short treatment courses and the absence of side effects 
make AmBisome the most attractive existing treatment for 
VL  [37].  However,  AmBisome  is  currently  also  the  most 
expensive treatment option for VL, and, therefore, inaccessible 
for most endemic countries, although the manufacturer has 
made  the  product  available  for  a  discounted  price  for  the 
treatment of patients in low and middle income countries. 
In  developed  countries,  where  cost  is  not  a  limitation, 
AmBisome is the drug of choice for VL.
A  regimen  of  20  mg/kg  (total  dose)  of  AmBisome  was 
recommended based on previous experience in different parts 
of the world in treating patients  [37]. However, lower doses 
may be sufficient for the Indian subcontinent. In India, in a 
small study, a single dose of 5 mg/kg of AmBisome was effec-
tive in 91% of patients [52]. In MSF’s African VL programs, in 
which AmBisome is used as second-line therapy, a regimen 
of 25 – 30 mg/kg total dose is often needed to achieve cure [53]. 
Data on AmBisome’s efficacy are anecdotal, or based on small 
trials, and no dose-finding studies for AmBisome have taken 
place in any region. A dose finding study into the efficacy of 
a  single  dose  is  now  in  progress  in  East  Africa  by  DNDi 
and partners.
Because  of  its  safety,  MSF  is  able  to  use  AmBisome 
successfully  in  very  basic  field  conditions  in  Sudan  [54,55] 
and Ethiopia [56]. In India (Bihar), AmBisome is used as first-
line regimen by MSF with an initial cure rate of 99%  [57]. 
AmBisome is also in use by MSF as first-line treatment in 
Ethiopian HIV/VL coinfected patients in whom it was shown 
to be safe, but it lacks efficacy, with 18% parasitological failure 
in primary VL, and > 50% failure among relapsing HIV/VL 
patients [56].
Several  other  lipid  forms  have  been  evaluated  in  VL, 
such as Abelcet® (the Liposome Co., Princeton, NJ, USA), 
Amphocil®  (Intermune,  Brisbane,  CA,  USA),  Fungisome® 
(Lifecare, India) and Amphomul® (Bharat Serums and Vac-
cines, India). None of these lipid formulations have yet been 
compared to AmBisome in a clinical trial. In a small study, 
safety and efficacy of Amphomul were similar to AmBisome [58] 
and if the price is competitive, it may form a future alterna-
tive to AmBisome. A promising oral form of amphotericin B is 
in an early stage of development by DNDi and partners.
AmBisome accumulates in tissues and is only slowly released 
and excreted [59]. This would theoretically increase the risk of 
resistant strains, but despite extensive use in VL, no in vivo 
resistance has yet been identified. This is likely to be due to the 
fact that parasites are killed very quickly by AmBisome, and 
thus get little opportunity to develop into resistant strains.
3.4	 MF
MF (hexadeclyphosphocholine, Impavido®) is an alkylphos-
phocholine  that  was  originally  developed  as  an  anticancer 
agent  in  the  early  1980s.  In  the  mid-1980s,  its  potential 
activity for VL was identified and registration was achieved 
in India in 2003 through collaboration between the manu-
facturer Zentaris, Research and Training in Tropical Diseases 
by TDR and the government. MF is registered in India, the EU 
and most Latin American countries, but not yet elsewhere 
in Asia or in Africa.
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A Phase IV trial in India in > 1100 patients reported 
an efficacy of between 82% (intention-to-treat) and 95% (per-
protocol)  [60].  Vomiting  occurred  in  8%  and  diarrhea  in 
5.7% of patients, but serious side effects requiring hospitaliza-
tion occurred in < 1%. Mild renal impairment, probably as 
a consequence to dehydration caused by diarrhea and vomiting, 
occurred in ∼ 15% and was severe in ∼ 1%. Elevated liver 
enzymes occurred in ∼ 30%, and hepatotoxicity was severe 
in ∼ 1%.
A randomized-controlled trial in Ethiopia showed that MF 
was safe and effective in HIV-negative VL patients (94% initial 
cure), but lacked efficacy in HIV-positive patients (78% ini-
tial cure). Although SbV was more effective, MF was safer in 
this group of patients. Receiving SbV increased the risk of death 
by a factor of 6.53 (95% CI 2.5 – 16.9) [18].
Teratogenicity  remains  a  concern  and  limitation  of  the 
drug. Whilst only demonstrated in three animal models, and 
whilst two women had apparently normal babies during the 
Phase  IV  trial  [60],  it  remains  imperative  to  use  prolonged 
contraception when using MF in women of child-bearing age. 
Contraception has conventionally been given for 2 – 3 months 
post treatment, but a new finding of a long terminal half-life 
of over 30 days meant sub-therapeutic concentrations of MF 
continued to be detected beyond 5 months after treatment [61]. 
This suggests that contraception should be given for > 3 months, 
and when this is not feasible, or unlikely to be strictly practiced, 
MF should be avoided in women of child-bearing age.
Resistance was shown to relatively easily develop in vitro 
through a single point mutation [62]. The long terminal half-life 
of MF has the potential to increase the risk of the development 
of  resistant  strains,  especially  if  it  is  used  in  incomplete 
courses and if relapses are not thoroughly re-treated. Although 
a compliance of 95.5% was reported in the Phase IV study, 
in  a  pilot  roll  out  of  MF  in  India  20  –  33%  of  patients 
discontinued treatment despite financial incentives (personal 
communication, S Sundar). Low adherence to therapy may 
promote  resistance,  and  strategies  to  prevent  this  include 
administration  only  in  settings  in  which  directly  observed 
treatment is feasible.
3.5	 Pentamidine
Since the 1940s, pentamidine has been successfully used against 
different forms of leishmaniasis, but was later abandoned as 
first-line treatment for VL, due to the development of resis-
tance in India and the availability of other drugs with less 
side effects [63]. It is currently used as secondary prophylaxis 
in monthly or biweekly administration in HIV/VL patients. 
Ideally, secondary prophylactic regimen should be effective, 
easy to administer, have minimal interactions with HAART, 
have  minor  toxicity  in  HIV  positive  patients  and  not  be 
needed as treatment of relapses. Pentamidine is well-distributed 
in tissues and excreted very slowly  [64,65]. Data on efficacy 
are scarce, but reduction of relapses and good tolerability of 
pentamidine  monthly  injections  are  reported  [66-68]. These 
characteristics  and  its  low  toxicity  in  intermittent  dosing 
regimen make it suitable for secondary prophylaxis. Pentamidine 
is donated for the treatment of neglected diseases in devel-
oping countries, and will thus be a cost-effective option in 
prophylactic regimen. Clinical trials on the prophylactic effect 
of  pentamidine  (and  other  drugs)  in  HIV/VL  coinfected 
patients are needed. However, this should not delay immediate 
implementation of secondary prophylaxis on a compassionate 
Table	3.	Target	profile	for	developing	combinations	from	existing	VL	treatments	(reproduced	with	the	permission		
of	DNDi).
Target Minimum	acceptable
Leishmania species All species Leishmania	donovani (anthroponotic endemic areas)
Distribution All areas One region (India, Africa or South America)
Target population Immunocompetent and immunosuppressed,
adults and children
Immunocompetent
Primary VL
Adults and children
Treatment regimen 10 days 14 days
Feasibility Mostly given as out-patient  
(e.g., oral treatment)
Daily ambulatory care possible (e.g., daily i.m. 
injections)
Clinical efficacy > 95% cure at 6 months > 90% cure at 6 months or > 95% initial cure if 
follow-up incomplete
Resistance Active against resistant strains Active against resistant strains
Safety and tolerability No AEs requiring in patient monitoring Deaths during treatment < 1%
Contraindications None Pregnancy/lactating
Cost per treatment  
(2008 prices)
< $75/course < $175/course (only if other cost saving possible 
through reduction in opportunity costs to patient and 
hospital care)
AE: Adverse event; DNDi: Drugs for Neglected Diseases initiative; i.m.: Intramuscular; VL: Visceral leishmaniasis.
E
x
p
e
r
t
 
O
p
i
n
.
 
E
m
e
r
g
i
n
g
 
D
r
u
g
s
 
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 
w
w
w
.
i
n
f
o
r
m
a
h
e
a
l
t
h
c
a
r
e
.
c
o
m
 
b
y
 
A
s
h
l
e
y
 
P
u
b
l
i
c
a
t
i
o
n
s
 
L
t
d
 
o
n
 
0
9
/
0
2
/
0
9
 
F
o
r
 
p
e
r
s
o
n
a
l
 
u
s
e
 
o
n
l
y
.den	Boer,	Alvar,	Davidson,	Ritmeijer	&	Balasegaram
	 Expert	Opin.	Emerging	Drugs	(2009) 14(3)  403
basis for coinfected patients who are otherwise unlikely to 
survive their continuing VL relapses [23].
4.	 Current	research	goals
As there are no novel compounds expected to be approved 
in the next 5 years, efforts should be made to preserve the 
efficacy  of  currently  available  drugs,  and  combination 
regimen should be evaluated. Preferably, these regimens should 
be  <  2  weeks  duration  to  maximize  compliance,  matched 
pharmacokinetically to minimize the chance of development of 
resistance to a single component, affordable, so that roll out on 
a large scale is possible, and orally administered. Table 3 gives 
an overview of the target and minimally acceptable criteria 
for combination regimen.
5.	 Scientific	rationale
5.1	 Combination	regimen
Combination  regimens  have  widely  and  successfully  been 
applied for the treatment of infectious diseases such as tuber-
culosis and malaria, and this has formed the rationale for the 
same approach in VL. Combinations have a broader clinical 
efficacy,  through  the  combined  effect  of  compounds  with 
different mechanisms of action, and also, ideally, through a 
synergistic effect. Combination regimens also reduce toxicity 
by allowing for lower doses of the individual drugs, and are 
expected to delay resistance.
Drug combinations should be tested in vitro to exclude 
antagonism,  and  should  not  have  overlapping  or  additive 
toxicity. From their toxicity profiles, combinations of PM + MF, 
AmBisome + PM and AmBisome + MF are predicted to be as 
safe as the single drugs. Preclinical evaluations of combinations 
indicated potentiation of MF + amphotericin B; no significant 
potentiation was seen for SbV + MF. Multidrug regimen of 
interest were identified as AmBisome + MF, AmBisome + PM 
and PM + MF [69]. Combinations should ideally be matched 
pharmacokinetically to avoid the exposure of parasites to low 
concentrations  of  a  single  drug.  PM,  with  an  elimination 
half-life of 2.6 h will not optimally protect MF, which has a 
very long half-life and is still detectable in plasma of patients 
5 – 6 months after treatment [61]. In contrast, AmBisome has 
a very long tissue half-life in spleen and liver, and is not prone 
to the development of resistance. A suitable regimen would be 
to start with a single dose of AmBisome, followed by another 
drug.  An  Indian  dose-ranging  study  applied  this  principle 
with  AmBisome  3.75  or  5  mg/kg  +  MF,  and  found  cure 
rates > 90%, irrespective of the duration of days of MF (7, 10 
or 14 days)  [70]. In the Indian context, this is as expected 
considering  the  high  efficacy  (>  90%)  of  a  single  dose  of 
AmBisome at 5 mg/kg [52]; however, the value of combination 
studies in preventing resistance will not be apparent from 
studies designed to evaluate efficacy only.
The combination of PM + SSG (a 17-day combination 
regimen of PM 15 mg/kg/day plus SSG 20 mg/kg/day) has 
been extensively used and this combination was shown in 
clinical trials to be more effective than monotherapy with 
either drug [40,46,71]. MSF started to use this regimen in 1991 
to cope with a large VL epidemic in South Sudan. Retrospective 
data of > 3000 patients showed that this combination was safer 
than and as effective as SSG alone (> 97%)  [39]. Compared to 
1268  patients  treated  with  SSG,  combination  therapy  was 
associated with greatly reduced odds of death, and less diarrhea 
and bleeding during treatment. The combination is now being 
assessed in a clinical trial in Africa by DNDi and partners. 
Preliminary results suggest an efficacy of just over 90%.
Table 4 shows the continuing studies of different combination 
regimen in India and Africa (studies in South America will 
Table	4.	Continuing	and	planned	combination	VL	treatment	studies.
Combination Study	location Research	performed	by Dose Results	expected
AmBisome + MF
AmBisome + PM
MF + PM
India, Bangladesh,  
Nepal
DNDi and partners 1 day AmBisome 5 MK + 7 days MF
1 day AmBisome 5 MK + 10 days  
PM 15 MK
10 days MF + 10 days PM 15 MKD
Study continuing. Phase III 
in India early 2010, 
Phase IV in all three 
countries in 2011
AmBisome + MF East Africa DNDi and partners 1 day AmBisome 10 MK +  
10 days MF
Study planned. Registration 
of AmBisome and MF in 
2011; results Phase III 2014
AmBisome + MF India, planned for 
Bangladesh
WHO TDR/Paladin/ICMR 1 day AmBisome 5 MK +  
14 days MF
March 2009 in India
AmBisome + SbV East Africa DNDi and partners 1 day AmBisome 10 MK +10 days  
SbV 20 MKD
Study planned;
results Phase III 2014
SbV + PM East Africa DNDi and partners 17 days SbV 20 MKD + 17 days  
PM 15 MKD
Study continuing. PM 
registration 2010;
results Phase IV 2012
DNDi: Drugs for Neglected Diseases initiative; ICMR: Indian Council of Medical Research; MF: Miltefosine; MK: mg/kg; MKD: mg/kg/day; PM: Paromomycin;  
Sbv: Pentavalent antimonials; TDR: WHO’s Special Programme for Research and Training in Tropical Diseases; VL: Visceral leishmaniasis.
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be  initiated  in  2010  by  DNDi).  Combination  therapy 
should  be  implemented  widely  as  soon  as  results  of  these 
studies are known. In the interim period, monotherapy will 
have to be used. To minimize the risk of resistance, mono-
therapy should be carefully supervised to ensure adherence, 
initial and final cures, and effective treatment of relapses.
None of the combination regimens currently under study 
has  the  advantage  of  two  oral  drugs.  A  short  course  oral 
combination regimen is the preferred option. With an oral 
form of amphotericin B, this could become possible in the 
form of an oral amphotericin B + MF treatment regimen.
5.2	 Novel	drugs
In  VL,  the  drug  target  is  the  amastigote  that  lives  and 
multiplies intracellularly (in human macrophages). The exact 
mechanism of action of most VL drugs is unknown (Table 5). 
Despite the extensive knowledge about the biology and chem-
istry of the parasite, there is a lack of knowledge on drug-
parasite interactions, and only few targets for drug development 
have been validated [72,73]. This is expected to improve once 
the genome of the Leishmania parasite is known.
Possible  lead  compounds  that  show  in  vitro  activity  are 
constantly being identified, but resources to bring them for-
ward to the preclinical and clinical stage are missing. New 
compounds that have entered the clinical phase are either a 
result of alternative formulations of existing drugs (liposomal 
amphotericin B, lipid emulsion of amphotericin B) or use of 
known drugs (therapeutic switching) resulting in the discovery 
of VL activity of PM, amphotericin B and MF. In all cases, the 
preclinical work was already done. Other known drugs that 
were identified and brought forward to the preclinical phase 
are  the  antileishmanial  biphosphonates  and  the  antifungal 
azoles (fluconazole and other azoles); albeit, the former have 
not been demonstrated to be effective, except risedronate [74], 
and the latter had disappointing results [75].
Presented in Figure 2 and Table 5 are overviews of com-
pounds in development. Oral amphotericin B is currently being 
assessed in Phase I as well as undergoing (animal) efficacy 
studies for VL. The drug could be considered for Phase II 
development by the end of 2009. Sitamaquine has undergone 
Phase II trials but issues remain about safety and relatively 
limited  efficacy  (under  90%).  Even  with  an  optimistic 
clinical development scenario, it is unlikely that either will 
be registered for VL before 2014. Another oral formulation 
of amphotericin B (iCo) and buparvaquone are currently in 
preclinical development. If successful, both are likely to be 
registered well after 2014.
To create a more robust pipeline, DNDi has invested in 
high-throughput in vitro screening of compounds in mac-
rophage  amastigote  models  (in  partnership  with  Institut 
Pasteur, Korea). Druggable candidates will be further devel-
oped by a newly established drug discovery consortium (with 
Advinus Therapeutics, India and the Central Drug Research 
Institute, India, as main partners). At least one new candidate 
for clinical testing is expected to be delivered in 2011 – 12.
6.	 Competitive	environment
See Figure 2 and Table 5.
7.	 Potential	development	issues
See Table 5.
8.	 Conclusion
Current  research  for  VL  has  mainly  been  focused  on  the 
biological aspects of the parasite, an approach that is not of 
benefit to the many patients who need treatment today and 
not  targeted  to  identifying  promising  new  drugs.  However, 
with the foundation of iOWH and DNDi, prospects have been 
improving. Clinical trials testing the efficacy of combinations 
of existing drugs are in progress, while there are now several 
new  compounds  in  the  research  pipeline.  Drug  screening 
programs for VL have received a financial boost; three highly 
effective  new  treatments  for  VL  were  identified  through 
therapeutic  switching  and  have  been  licensed  in  the  past 
10 years. However, translation of these results in VL control 
programs  in  the  developing  world  is  still  painfully  lacking 
and  is  an  area  deserving  of  immediate  and  urgent  atten-
tion,  especially  in  the  context  of  the  rapidly  expanding 
HIV/VL coinfection.
9.	 Expert	opinion
Now  that  the  clinical  development  of  PM  and  MF  has 
been completed, and affordable, easy-to-use rapid diagnostic 
tests  for  VL  are  available  (the  rk39  immunochromato-
graphic  test)  [76],  the  viability  of  large  scale  treatment 
programs is greatly increased. Based on this notion, in 2004, 
a  memorandum  of  understanding  was  signed  between 
Bangladesh,  Nepal  and  India  to  reduce  the  incidence  of 
VL to < 1 case/10,000 individuals in 2015 [77]. Elimination 
plans were drawn, combining mass diagnosis and treatment, 
vector management, an effective surveillance system, opera-
tional research and social mobilization. Funds for the Indian 
program  have  been  committed  by  the  Indian  government 
and the World Bank. However, 5 years after initiation of the 
plans, roll out is only very slowly underway. Better control 
of VL is feasible with the currently available tools and the 
Asian elimination strategy should be implemented with much 
more  urgency.  The  strategy  should  also  be  adapted  and 
followed in other endemic regions. Plans are already being 
drawn in South America and the Middle Eastern regions, and 
the African region should be supported to develop a regional 
approach as well. At the same time, lessons need to be learnt 
from the leprosy eradication program in which the pressure 
to reach the target resulted in significant under-reporting of 
cases [78]. Next to elimination initiatives, there is a place for 
programs  that  intend  to  limit  VL  mortality  today.  In  the 
African VL endemic region, where health systems are poorly 
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functional or non-existent, any elimination program will be 
difficult and slow to implement. Immediate interventions in 
outbreaks, with active case finding, diagnosis and treatment, 
are urgent and necessary. A more adequate outbreak response 
system should be developed to reduce mortality.
Any large scale treatment program should preferably make 
use of combination regimen. However, as these are not yet 
fully  clinically  evaluated,  an  interim  strategy  is  needed,  in 
which  the  best  available  evidence  is  used  to  guide  therapy, 
and in which monotherapies will still have to feature. Clearly, 
different  drugs  and  drug  combinations  will  be  needed  in 
different  settings.  For  the  African  region,  where  SbV  still 
works, the SSG + PM (17 days) combination, of which the 
efficacy is already known, is preferred. PM should, therefore, 
be  registered  in  this  region  as  soon  as  possible.  For  the 
Indian subcontinent, MF monotherapy as first-line treatment 
is intended for the elimination program. However, to pro-
tect MF from resistance, its use in monotherapy should be 
restricted to programs in which adherence to therapy can be 
supervised.  Roll  out  in  the  endemic  areas  of  the  Indian 
subcontinent before this can be guaranteed will create a real 
risk of ‘losing’ MF as a viable treatment option. AmBisome 
monotherapy, with its low risk of resistance and short duration 
of  treatment,  may  be  a  more  suitable  interim  regimen  for 
the Asian elimination programs, especially if it proves to be 
effective in a single dose regimen, which would offer great 
practical advantages in terms of reduced hospital time and 
guaranteed compliance that should be weighed against the 
increased  cost  of  treatment.  AmBisome  roll  out  requires 
resources (trained nurse) and a cold-chain, but despite this 
MSF  is  successfully  implementing  AmBisome  as  first-line 
therapy in India. PM roll out is being piloted by iOWH 
in India, and might prove to be another suitable choice, as 
long as compliance can be guaranteed. Prevention of resis-
tance also needs to include monitoring of the effectiveness of 
treatment, relapse rates and cure rates of relapsed patients, 
and  the  establishment  of  a  method  for  in  vitro  drug 
susceptibility testing.
When large scale treatment programs become a reality, it 
will be necessary for manufacturers to significantly upscale the 
production of VL drugs. Most of these are only produced 
by a single manufacturer (Table 1). At present, there is little 
demand  for  most  VL  drugs  and,  therefore,  production  is 
irregular and orders can face long delays. Manufacturers are 
not prepared for a significant increase in demand and will 
demand reliable forecasts before upgrading their production. 
These  forecasts  can  only  be  made  through  a  coordinated 
estimation of needs for different endemic regions. There is, 
therefore, a need for a central faculty in which estimations of 
needs are made, orders are pooled and from which all VL drugs 
are readily available. Pooled demands and reliable forecasts 
will make the timely manufacturing of batches possible, and 
drugs will be obtained at lower prices by this faculty as they 
can  be  bought  in  large  quantities,  which  will  generate 
considerable negotiation power. This faculty will be able to 
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Preclinical
efficacy & safety
Registration Clinical Ph IV
• DNDi projects
• Non-DNDi projects
VL combo
Asia 
Buparvaquone
Oral
ampho B
(BDSI)
PM-SSG
Africa 
PM – India
(iOWH)
Amphomul
(Bahrat)
Miltefosine
Africa
AmBisome®
Africa 
Combination studies
8-aminoquinolones
(GSK)
Oral ampho B
(iCo)
Single-dose
AmBisome®
10 mg/kg
(Sundar)
Figure	2.	Drugs	currently	in	preclinical	and	clinical	development	for	VL.
Courtesy of Drugs for Neglected Diseases initiative. 
VL: Visceral leishmaniasis.
supply sufficient quantities of drugs without delay in case of 
outbreaks, as well as the relatively small amounts that are 
needed for small scale treatment programs. Lack of access 
to  drugs  due  to  temporary  quality  problems  or  a  lack  of 
registration (Table 2a, b) is a recurring problem experienced 
in VL treatment programs. Such a faculty should also take the 
lead in tackling these access issues. WHO’s role as coordinating 
agency should be emphasized and WHO should take the lead 
in establishing such a faculty.
The prices of most VL drugs are high and WHO should 
continue to negotiate with manufacturers, as they have suc-
cessfully done recently. Generic production should be pro-
moted  to  increase  competition  and  remedy  the  vulnerable 
situation  in  which  VL  drugs  are  only  produced  by  one 
manufacturer.  To  guard  against  unregulated  use,  the  cash 
value of antileishmanial drugs needs to be minimized by the 
provision of free treatment to patients.
The problem of HIV/VL coinfection should be addressed 
with  urgency.  VL  should  be  universally  recognized  as  an 
opportunistic infection in HIV. As for now, only AmBisome 
and  MF  can  safely  be  used  for  the  treatment  of  HIV/VL 
coinfected patients, and access to these drugs in treatment 
programs is crucial. In Ethiopia, the country with the highest 
prevalence of HIV/Leishmania coinfections, MF is currently 
not registered and can, therefore, not be used. Testing and 
prevention of HIV should become a priority in any VL treat-
ment programs. The scientific community should be mobilized 
and public attention should be focused on this emerging public 
health problem.
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